Lv75
4565 积分 2020-04-09 加入
Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
5小时前
已完结
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
6小时前
已完结
Minimising the potential for metabolic activation in drug discovery
6小时前
已完结
Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs
6小时前
已完结
Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
1天前
求助中
Discovery of oxazolidinone-based heterocycles as subtype selective sigma-2 ligands
1天前
已完结
Discovery of novel, selective, functionalized 5-(2-(5-arylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethyl)-γ-butyrolactone sigma-2 ligands
1天前
已完结
Selectivity profile comparison for certain γ-butyrolactone and oxazolidinone-based ligands on a sigma 2 receptor over sigma 1: a molecular docking approach
1天前
已完结
Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules
1天前
已完结
The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review
1天前
已完结
皖公网安备34019202002308
